|Bid||4.22 x 900|
|Ask||4.75 x 900|
|Day's Range||4.16 - 4.37|
|52 Week Range||4.06 - 16.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.33|
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials addressing multi-drug resistant gram-negative ...
--Company presentation scheduled for October 2, 2018 at 1:40 p.m. EDT--. SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018-- Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing ...
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018-- Achaogen, Inc., a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today highlighted ...
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Northeast ...
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference taking place August 14 to 15, 2018 in New York City. Achaogen management will present at 8:00 a.m. Eastern Time on Tuesday, August 14th, 2018. A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com.
Inc., a publicly traded drug company that has received financial support from the Bill & Melinda Gates Foundation, raised a “going concern” warning in a regulatory filing Monday, alerting investors it is starting to run low on cash. The South San Francisco, Calif.-based company, which last month said it plans to cut more than a quarter of its workforce, said it had unrestricted cash, cash equivalents and short-term investments of $100.5 million and an accumulated deficit of $470 million. Achaogen said it would try to raise additional funds through equity or debt financings, government contracts, collaborations and commercial sales of Zemdri, its only approved product and which became available last month.
Achaogen (AKAO) delivered earnings and revenue surprises of -30.43% and 71.95%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.20. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
--ZEMDRI, approved in the U.S. for the treatment of adults with complicated urinary tract infections--. --Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To ...
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ZEMDRI when administered in the hospital inpatient setting. In the final rule concerning Hospital Inpatient Prospective Payment Systems and Fiscal Year 2019 Rates, CMS stated that “ZEMDRI offers a substantial clinical improvement for patients who have limited or no alternative treatment options because it is a new antibiotic that offers a treatment option for a patient population unresponsive to currently available treatments” and that “ZEMDRI meets all the criteria for approval of new technology add-on payments.” Additional information on the final rule and its discussion of NTAP and ZEMDRI can be found online at: HIPPS.
Achaogen is the second Bay Area company this month hit by overarching trends in the antibacterial market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 26) ADMA Biologics Inc (NASDAQ: ADMA )(announced it has addressed ...
Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced a strategic update and corporate restructuring to focus resources on the successful commercialization of ZEMDRITM in the United States, the Marketing Authorization Application (MAA) filing for ZEMDRI in the European Union, and continued development of the C-Scape program. Consistent with the Company’s mission, Achaogen’s research and development efforts will focus on C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, and new aminoglycoside antibiotics, both of which have non-dilutive funding commitments.
The pieces have begun to come together for South San Francisco’s biotech space puzzle. Here’s the latest info on who’s doing what where.
SOUTH SAN FRANCISCO, Calif., July 24, 2018-- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, ...
--ZEMDRI now available for ordering in the U.S.--. --ZEMDRI demonstrated in vitro microbiological activity against pathogens designated by the CDC as urgent and serious public health threats, including ...
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, will host a lunch updating investors on the market opportunities for plazomicin, including the treatment of serious bacterial infections due to MDR Enterobacteriaceae with perspectives from key opinion leaders Steven Burdette, M.D. and Joshua Rosenberg, M.D., on Thursday, July 12, from 12:00pm – 1:30pm Eastern Time in New York City. Achaogen management will present an update on the commercial strategy for ZEMDRITM(plazomicin), which recently received U.S. Food and Drug Administration (FDA) approval for treating adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options.
ViewRay (VRAY) is focused on manufacturing and commercializing MRIdian, its magnetic resonance (or MR) image-guided radiation therapy system, which uses MRI and external beam radiation therapy to concurrently image and treat cancer patients. In February 2017, it received 510(k) clearance from the Food and Drug Administration (or FDA) to market MRIdian Linac. In July 2018, six of the total seven analysts covering ViewRay have given the stock a “buy” or higher rating, while one analyst has given it a “sell” rating.
Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options. As the first once-daily aminoglycoside therapy approved for cUTI , this drug is expected to target the unmet demand from patients suffering from certain multidrug-resistant Enterobacteriaceae. Achaogen estimates the annual inpatient market opportunity for Zemdri in the United States at around 450,000 patients. Despite this favorable news, Achaogen witnessed an almost 20% drop in its share price from $12.02 on June 25 to $9.59 on June 26.
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company's next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).